Compare Shattuck Labs, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 281 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.91
-58.79%
3.01
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
84.97%
0%
84.97%
6 Months
380.68%
0%
380.68%
1 Year
190.24%
0%
190.24%
2 Years
-62.89%
0%
-62.89%
3 Years
-16.2%
0%
-16.2%
4 Years
-37.53%
0%
-37.53%
5 Years
-92.71%
0%
-92.71%
Shattuck Labs, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.31%
EBIT Growth (5y)
-1.74%
EBIT to Interest (avg)
-74.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.89
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.94%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.81
EV to EBIT
0.07
EV to EBITDA
0.08
EV to Capital Employed
-0.70
EV to Sales
-1.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-104.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 18 Schemes (9.99%)
Foreign Institutions
Held by 27 Foreign Institutions (5.92%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.00
1.60
-100.00%
Operating Profit (PBDIT) excl Other Income
-12.10
-22.00
45.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.50
-21.60
42.13%
Operating Profit Margin (Excl OI)
0.00%
-14,271.00%
1,427.10%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -100.00% vs 700.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 42.13% vs -1.41% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5.70
1.70
235.29%
Operating Profit (PBDIT) excl Other Income
-76.50
-87.90
12.97%
Interest
0.00
0.00
Exceptional Items
-0.20
0.00
Consolidate Net Profit
-75.40
-87.30
13.63%
Operating Profit Margin (Excl OI)
-14,043.90%
-55,496.10%
4,145.22%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 235.29% vs 142.86% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 13.63% vs 14.33% in Dec 2023
About Shattuck Labs, Inc. 
Shattuck Labs, Inc.
Pharmaceuticals & Biotechnology
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of dual-sided fusion proteins. The Company has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The Company's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.
Company Coordinates 
Company Details
1018 W. 11Th Street, Suite 100 , AUSTIN TX : 78703
Registrar Details






